A proposed one-million-genome programme for the world's fifth most populous country. Delivered in-country. Owned by the State and its citizens. Governed by Pakistanis. Built to be the reference standard for how a sovereign genome programme is run.
Pakistan has more than 240 million people and one of the highest rates of consanguinity in the world. Yet it is close to absent from global genomic datasets. Few populations of this size combine a high frequency of recessive disease genes with naturally occurring human knockouts. These are the variants that show whether a drug target is safe to inhibit. A Pakistan National Genome Programme is not a regional study. It is a missing foundation of human genetics.
A 400-genome long-read pilot and the first Pakistani pangenome, sequenced entirely in Pakistan. 12–15 Pakistani scientists trained and certified. A laboratory and secure data environment that remain a national asset. All designed to lead into a one-million-genome national programme. The programme was submitted to the Government of Pakistan as an unsolicited proposal under its Public Procurement Rules. Discussions are advanced. The technical team is mobilised and ready to deploy.
One million whole genomes, proposed across four phases over roughly seven years. Sequenced with long-read technology at 30× coverage. A T2T Pakistani pangenome (a population-specific reference built from the cohort's own haplotypes) replaces a European-anchored reference that mismaps South Asian variation.
Submitted as an unsolicited proposal under Pakistan's Public Procurement Rules: a privately financed programme with no call on the public purse, brought under a lawful procurement route.
The State owns the data. A national laboratory network operates collection and sequencing through a locally majority-owned joint venture. LydiaRx supplies the sovereign platform, analytics, supply chain and governance design. No sample and no raw genomic data leaves Pakistan.
The pilot sequences 400 whole genomes at 30× long-read coverage over six to nine months. It builds the first Pakistani T2T pangenome from them. It is sized to prove the platform, the consent model and the reference method before scale. Consent is tiered and runs in Urdu and regional languages. A Pakistani-majority Data Access Committee decides every use of the data. Ethics approval comes before the first participant is approached. Independent audits are published at months three and nine. The pangenome is released open-access from Pakistani soil. No output is commercialised before the government agreement is signed. Every discovery from the pilot is royalty-free to Pakistan's health system.
Analysis comes to the data. The data never leaves. Atlas holds raw signal, alignments and variants on in-country infrastructure. It answers each approved question inside the environment. Phylax admits each analysis only against purpose, consent and entitlement. It meters what leaves and writes every action to a ledger the State can verify. Prism keeps every report consistent with one versioned body of evidence.
The State and its citizens. LydiaRx acts as authorised custodian.
The Government of Pakistan.
Collection, biobanking and sequencing, run through a national laboratory network via a locally majority-owned joint venture.
LydiaRx: the sovereign platform, analytics, supply chain, financing structure and governance design.
A Governance and Ethics Board with Pakistan-resident clinical and academic co-leads, and a Pakistani-majority Data Access Committee that decides every use of the data.
Pakistan is the foundation programme, not the limit. Every element is designed for reuse: the custody architecture, the consent model, the oversight structure and the licensing model for governed outputs. Any nation that wants its genome to be its own asset can use them.
Start with a briefing. It commits you to nothing.